Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

20 evidence topics · 16 sources

Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels
Infection, hepatitis, and immunization requirements: deucravacitinib and icotrokinra labels
Laboratory and clinical monitoring: deucravacitinib, apremilast, and icotrokinra labels
Pregnancy, lactation, pediatric use, and geriatric use: deucravacitinib, apremilast, and icotrokinra labels
Renal and hepatic impairment: deucravacitinib, apremilast, and icotrokinra labels
Selectivity for TYK2 over JAK1, JAK2, and JAK3 across allosteric TYK2 inhibitors
Duration of TYK2 inhibition across the dosing interval and dosing frequency of TYK2 inhibitors
Efficacy and tolerability of deucravacitinib relative to apremilast and injectable biologics in narrative reviews
Head-to-head trial: risankizumab versus deucravacitinib in biologic-naive moderate psoriasis, week 16

“IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One potential limitation is that this study employs an open-label design rather than a double-blinded design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Network meta-analyses of TYK2 inhibitors and other oral agents
Absence of head-to-head trials and formal indirect comparisons that include envudeucitinib